Kymera Therapeutics Inc (NAS:KYMR)
$ 50.05 -1.84 (-3.55%) Market Cap: 3.24 Bil Enterprise Value: 2.90 Bil PE Ratio: 0 PB Ratio: 3.63 GF Score: 47/100

Kymera Therapeutics Inc To Discuss Data From KT-474 Phase 1 Trial Call Transcript

Oct 27, 2021 / 02:30PM GMT
Release Date Price: $56.61 (+0.16%)
Operator

Good morning. I'd like to welcome everyone to Kymera Therapeutics conference call. (Operator Instructions) The call is being webcast live on the Investor and Media section of Kymera's website at kymeratx.com. This call is the property of Kymera Therapeutics and recording and reproduction or transmission of this call without express written consent of Kymera Therapeutics is strictly prohibited. Please note, the call is being recorded. I would now like to hand the call over to your host today, Bruce Jacobs, Chief Financial Officer. Please begin.

Bruce N. Jacobs
Kymera Therapeutics, Inc. - CFO

Good morning, everyone, and thank you for joining us today on our call to discuss the new KT-474 Phase I clinical trial data that we released this morning at the TPD Summit. These data are summarized in a press release that we issued this morning.

Additionally, the press release and the presentation slides used on this call can be found on the Investors section of our website at kymeratx.com.

Starting on Slide 2 of the accompanying presentation. During

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot